SAN

77.09

+4.37%↑

ARGX

728

+2.56%↑

SHL.DE

34.73

+2.6%↑

PHIA

22.63

+2.91%↑

FRE

36.76

+1.38%↑

SAN

77.09

+4.37%↑

ARGX

728

+2.56%↑

SHL.DE

34.73

+2.6%↑

PHIA

22.63

+2.91%↑

FRE

36.76

+1.38%↑

SAN

77.09

+4.37%↑

ARGX

728

+2.56%↑

SHL.DE

34.73

+2.6%↑

PHIA

22.63

+2.91%↑

FRE

36.76

+1.38%↑

SAN

77.09

+4.37%↑

ARGX

728

+2.56%↑

SHL.DE

34.73

+2.6%↑

PHIA

22.63

+2.91%↑

FRE

36.76

+1.38%↑

SAN

77.09

+4.37%↑

ARGX

728

+2.56%↑

SHL.DE

34.73

+2.6%↑

PHIA

22.63

+2.91%↑

FRE

36.76

+1.38%↑

Accueil・Liste d'Actions・Genfit

Genfit

Ouvert

SecteurSoins de santé

9.45 6.66

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

8.58

Max

9.45

Chiffres clés
By Trading Economics
Revenu	-66M -76M
Ventes	-3.6M 32M
BPA	-1.525
Marge bénéficiaire	-237.939
Employés	188
EBITDA	-8M -7M

Recommandations
By TipRanks
Recommandations	Achat
Prévisions sur 12 Mois	+76.23% upside

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	53M 426M
Ouverture précédente	2.79
Clôture précédente	9.45

Sentiment de l'Actualité

By Acuity

48%

52%

152 / 344 Classement par Healthcare

Genfit Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

4 juin 2026, 21:51 UTC

Principaux Mouvements du Marché

Merlin Shares Rally After Defense Department's Design Review Wraps

4 juin 2026, 23:46 UTC

Market Talk

U.S. Jobs Data May Offer Bullish Catalyst for Dollar Vs. Yen -- Market Talk

4 juin 2026, 23:44 UTC

Market Talk

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

4 juin 2026, 23:42 UTC

Acquisitions, Fusions, Rachats

Energy Resources of Australia: Court to Decide on Rio Tinto Compulsory Acquisition Request

4 juin 2026, 23:41 UTC

Acquisitions, Fusions, Rachats

Energy Resources of Australia to Enter Trading Halt

4 juin 2026, 23:34 UTC

Market Talk

Oil Edges Lower Amid Mixed Middle East Developments -- Market Talk

4 juin 2026, 23:31 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

4 juin 2026, 23:31 UTC

Market Talk

Mercury NZ Loses Bull Despite Sector Earnings Powering Up -- Market Talk

4 juin 2026, 23:31 UTC

Market Talk

Global Equities Roundup: Market Talk

4 juin 2026, 23:08 UTC

Market Talk

Narrowing Rate Differentials Make Australian Dollar Less Attractive Versus USD -- Market Talk

4 juin 2026, 22:41 UTC

Market Talk

Australia Shares Set to Rise at the Open -- Market Talk

4 juin 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

4 juin 2026, 20:44 UTC

Acquisitions, Fusions, Rachats

RTX Stock Rises After Catching an Upgrade. Why This Analyst Is Bullish. -- Barrons.com

4 juin 2026, 20:16 UTC

Market Talk

Mexican Demand Indicators Show Signs of Life -- Market Talk

4 juin 2026, 20:15 UTC

Acquisitions, Fusions, Rachats

Gilead Sciences And Lakefront Complete Acquisition Of Ouro Medicines To Further Expand Inflammation Pipeline >GILD

4 juin 2026, 19:46 UTC

Market Talk

Treasury Yields Decline Ahead of U.S. Payrolls -- Market Talk

4 juin 2026, 19:38 UTC

Market Talk

Oil Futures Retreat After 3-Session Winning Streak -- Market Talk

4 juin 2026, 19:30 UTC

Market Talk

U.S. Natural Gas Futures Rise on Weather, Storage Data -- Market Talk

4 juin 2026, 18:47 UTC

Acquisitions, Fusions, Rachats

Google Stock Attracts Cathie Wood's ARK and Berkshire Hathaway. That's Rare. -- Barrons.com

4 juin 2026, 18:38 UTC

Résultats

Money Quote: Tech Weakness in Context -- WSJ

4 juin 2026, 18:24 UTC

Résultats

Quantinuum, Broadcom, UnitedHealth, and More Stocks That Explain Today's Market -- Barrons.com

4 juin 2026, 17:09 UTC

Market Talk

Retest of $55k Seen Possible for Bitcoin -- Market Talk

4 juin 2026, 16:58 UTC

Résultats

Broadcom, UnitedHealth, Blackstone, Ciena, and More Stocks That Explain Today's Market -- Barrons.com

4 juin 2026, 16:46 UTC

Market Talk

Strategy BTC Sale Continues to Weigh on Prices -- Market Talk

4 juin 2026, 16:38 UTC

Résultats

UnitedHealth Stock Rises. Why the Health Insurer Is Leading the Dow to Sharp Gains. -- Barrons.com

4 juin 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

4 juin 2026, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

4 juin 2026, 16:13 UTC

Market Talk

On Again, Off Again Deals Keep Oil Market on Edge -- Market Talk

4 juin 2026, 16:11 UTC

Market Talk

Copper Market Is Awaiting Key U.S. Tariff Decision -- Market Talk

4 juin 2026, 15:56 UTC

Market Talk

Copper Rises Amid Hormuz Disruptions, U.S. Stockpiling -- Market Talk

Comparaison

Variation de prix

Genfit prévision

Objectif de Prix

By TipRanks

76.23% hausse

Prévisions sur 12 Mois

Moyen 14.997 EUR 76.23%

Haut 15 EUR

Bas 15 EUR

Basé sur 1 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

1 ratings

Achat

Maintien

Vente

Basé sur 1 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Sentiment

By Acuity

152 / 344Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Genfit

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.